Global Anti-VEGF Intravitreal Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Anti-VEGF Intravitreal Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Anti-VEGF intravitreal drugs refer to a class of medications used in ophthalmology to treat various eye conditions characterized by abnormal blood vessel growth and leakage,notably wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,which work by blocking VEGF.These medications help reduce the growth of abnormal blood vessels,decrease vascular leakage, and thereby stabilize or improve vision.
This report is a detailed and comprehensive analysis for global Anti-VEGF Intravitreal Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Anti-VEGF intravitreal drugs refer to a class of medications used in ophthalmology to treat various eye conditions characterized by abnormal blood vessel growth and leakage,notably wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,which work by blocking VEGF.These medications help reduce the growth of abnormal blood vessels,decrease vascular leakage, and thereby stabilize or improve vision.
This report is a detailed and comprehensive analysis for global Anti-VEGF Intravitreal Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
- Global Anti-VEGF Intravitreal Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
- Global Anti-VEGF Intravitreal Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
- Global Anti-VEGF Intravitreal Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
- Global Anti-VEGF Intravitreal Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Anti-VEGF Intravitreal Drugs
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
- This report profiles key players in the global Anti-VEGF Intravitreal Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Biogen, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Qilu Pharma, Chengdu Kanghong Pharmaceutical, etc.
- This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Anti-VEGF Intravitreal Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.Market segment by Type
- Ranibizumab
- Aflibercept
- Conbercept
- Brolucizumab
- Faricimab
- Other
Market segment by Application
- Age-related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion
- Other
Major players covered
- Roche
- Novartis
- Biogen
- Coherus BioSciences
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Biocon Biologics
- Qilu Pharma
- Chengdu Kanghong Pharmaceutical
Market segment by region, regional analysis covers
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
- Chapter 1, to describe Anti-VEGF Intravitreal Drugs product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top manufacturers of Anti-VEGF Intravitreal Drugs, with price, sales quantity, revenue, and global market share of Anti-VEGF Intravitreal Drugs from 2021 to 2026.
- Chapter 3, the Anti-VEGF Intravitreal Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
- Chapter 4, the Anti-VEGF Intravitreal Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
- Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Anti-VEGF Intravitreal Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
- Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
- Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Intravitreal Drugs.
- Chapter 14 and 15, to describe Anti-VEGF Intravitreal Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-VEGF Intravitreal Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Ranibizumab
1.3.3 Aflibercept
1.3.4 Conbercept
1.3.5 Brolucizumab
1.3.6 Faricimab
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-VEGF Intravitreal Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Age-related Macular Degeneration
1.4.3 Diabetic Macular Edema
1.4.4 Retinal Vein Occlusion
1.4.5 Other
1.5 Global Anti-VEGF Intravitreal Drugs Market Size & Forecast
1.5.1 Global Anti-VEGF Intravitreal Drugs Consumption Value (2021 & 2025 & 2032)
1.5.2 Global Anti-VEGF Intravitreal Drugs Sales Quantity (2021-2032)
1.5.3 Global Anti-VEGF Intravitreal Drugs Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Anti-VEGF Intravitreal Drugs Product and Services
2.1.4 Roche Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Roche Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Anti-VEGF Intravitreal Drugs Product and Services
2.2.4 Novartis Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments/Updates
2.3 Biogen
2.3.1 Biogen Details
2.3.2 Biogen Major Business
2.3.3 Biogen Anti-VEGF Intravitreal Drugs Product and Services
2.3.4 Biogen Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Biogen Recent Developments/Updates
2.4 Coherus BioSciences
2.4.1 Coherus BioSciences Details
2.4.2 Coherus BioSciences Major Business
2.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product and Services
2.4.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Coherus BioSciences Recent Developments/Updates
2.5 Regeneron Pharmaceuticals
2.5.1 Regeneron Pharmaceuticals Details
2.5.2 Regeneron Pharmaceuticals Major Business
2.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product and Services
2.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.6 Samsung Bioepis
2.6.1 Samsung Bioepis Details
2.6.2 Samsung Bioepis Major Business
2.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product and Services
2.6.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Samsung Bioepis Recent Developments/Updates
2.7 Biocon Biologics
2.7.1 Biocon Biologics Details
2.7.2 Biocon Biologics Major Business
2.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Product and Services
2.7.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Biocon Biologics Recent Developments/Updates
2.8 Qilu Pharma
2.8.1 Qilu Pharma Details
2.8.2 Qilu Pharma Major Business
2.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Product and Services
2.8.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Qilu Pharma Recent Developments/Updates
2.9 Chengdu Kanghong Pharmaceutical
2.9.1 Chengdu Kanghong Pharmaceutical Details
2.9.2 Chengdu Kanghong Pharmaceutical Major Business
2.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product and Services
2.9.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ANTI-VEGF INTRAVITREAL DRUGS BY MANUFACTURER
3.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Anti-VEGF Intravitreal Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Anti-VEGF Intravitreal Drugs Manufacturer Market Share in 2025
3.4.3 Top 6 Anti-VEGF Intravitreal Drugs Manufacturer Market Share in 2025
3.5 Anti-VEGF Intravitreal Drugs Market: Overall Company Footprint Analysis
3.5.1 Anti-VEGF Intravitreal Drugs Market: Region Footprint
3.5.2 Anti-VEGF Intravitreal Drugs Market: Company Product Type Footprint
3.5.3 Anti-VEGF Intravitreal Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Anti-VEGF Intravitreal Drugs Market Size by Region
4.1.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2032)
4.1.2 Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2032)
4.1.3 Global Anti-VEGF Intravitreal Drugs Average Price by Region (2021-2032)
4.2 North America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.3 Europe Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.5 South America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
5.2 Global Anti-VEGF Intravitreal Drugs Consumption Value by Type (2021-2032)
5.3 Global Anti-VEGF Intravitreal Drugs Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
6.2 Global Anti-VEGF Intravitreal Drugs Consumption Value by Application (2021-2032)
6.3 Global Anti-VEGF Intravitreal Drugs Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
7.2 North America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
7.3 North America Anti-VEGF Intravitreal Drugs Market Size by Country
7.3.1 North America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
7.3.2 North America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Anti-VEGF Intravitreal Drugs Market Size by Country
8.3.1 Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
8.3.2 Europe Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Anti-VEGF Intravitreal Drugs Market Size by Region
9.3.1 Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
10.2 South America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
10.3 South America Anti-VEGF Intravitreal Drugs Market Size by Country
10.3.1 South America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
10.3.2 South America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Anti-VEGF Intravitreal Drugs Market Size by Country
11.3.1 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Anti-VEGF Intravitreal Drugs Market Drivers
12.2 Anti-VEGF Intravitreal Drugs Market Restraints
12.3 Anti-VEGF Intravitreal Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Anti-VEGF Intravitreal Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Intravitreal Drugs
13.3 Anti-VEGF Intravitreal Drugs Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-VEGF Intravitreal Drugs Typical Distributors
14.3 Anti-VEGF Intravitreal Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-VEGF Intravitreal Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Ranibizumab
1.3.3 Aflibercept
1.3.4 Conbercept
1.3.5 Brolucizumab
1.3.6 Faricimab
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-VEGF Intravitreal Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Age-related Macular Degeneration
1.4.3 Diabetic Macular Edema
1.4.4 Retinal Vein Occlusion
1.4.5 Other
1.5 Global Anti-VEGF Intravitreal Drugs Market Size & Forecast
1.5.1 Global Anti-VEGF Intravitreal Drugs Consumption Value (2021 & 2025 & 2032)
1.5.2 Global Anti-VEGF Intravitreal Drugs Sales Quantity (2021-2032)
1.5.3 Global Anti-VEGF Intravitreal Drugs Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Anti-VEGF Intravitreal Drugs Product and Services
2.1.4 Roche Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Roche Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Anti-VEGF Intravitreal Drugs Product and Services
2.2.4 Novartis Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments/Updates
2.3 Biogen
2.3.1 Biogen Details
2.3.2 Biogen Major Business
2.3.3 Biogen Anti-VEGF Intravitreal Drugs Product and Services
2.3.4 Biogen Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Biogen Recent Developments/Updates
2.4 Coherus BioSciences
2.4.1 Coherus BioSciences Details
2.4.2 Coherus BioSciences Major Business
2.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product and Services
2.4.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Coherus BioSciences Recent Developments/Updates
2.5 Regeneron Pharmaceuticals
2.5.1 Regeneron Pharmaceuticals Details
2.5.2 Regeneron Pharmaceuticals Major Business
2.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product and Services
2.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.6 Samsung Bioepis
2.6.1 Samsung Bioepis Details
2.6.2 Samsung Bioepis Major Business
2.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product and Services
2.6.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Samsung Bioepis Recent Developments/Updates
2.7 Biocon Biologics
2.7.1 Biocon Biologics Details
2.7.2 Biocon Biologics Major Business
2.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Product and Services
2.7.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Biocon Biologics Recent Developments/Updates
2.8 Qilu Pharma
2.8.1 Qilu Pharma Details
2.8.2 Qilu Pharma Major Business
2.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Product and Services
2.8.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Qilu Pharma Recent Developments/Updates
2.9 Chengdu Kanghong Pharmaceutical
2.9.1 Chengdu Kanghong Pharmaceutical Details
2.9.2 Chengdu Kanghong Pharmaceutical Major Business
2.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product and Services
2.9.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ANTI-VEGF INTRAVITREAL DRUGS BY MANUFACTURER
3.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Anti-VEGF Intravitreal Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Anti-VEGF Intravitreal Drugs Manufacturer Market Share in 2025
3.4.3 Top 6 Anti-VEGF Intravitreal Drugs Manufacturer Market Share in 2025
3.5 Anti-VEGF Intravitreal Drugs Market: Overall Company Footprint Analysis
3.5.1 Anti-VEGF Intravitreal Drugs Market: Region Footprint
3.5.2 Anti-VEGF Intravitreal Drugs Market: Company Product Type Footprint
3.5.3 Anti-VEGF Intravitreal Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Anti-VEGF Intravitreal Drugs Market Size by Region
4.1.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2032)
4.1.2 Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2032)
4.1.3 Global Anti-VEGF Intravitreal Drugs Average Price by Region (2021-2032)
4.2 North America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.3 Europe Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.5 South America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
5.2 Global Anti-VEGF Intravitreal Drugs Consumption Value by Type (2021-2032)
5.3 Global Anti-VEGF Intravitreal Drugs Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
6.2 Global Anti-VEGF Intravitreal Drugs Consumption Value by Application (2021-2032)
6.3 Global Anti-VEGF Intravitreal Drugs Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
7.2 North America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
7.3 North America Anti-VEGF Intravitreal Drugs Market Size by Country
7.3.1 North America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
7.3.2 North America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Anti-VEGF Intravitreal Drugs Market Size by Country
8.3.1 Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
8.3.2 Europe Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Anti-VEGF Intravitreal Drugs Market Size by Region
9.3.1 Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
10.2 South America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
10.3 South America Anti-VEGF Intravitreal Drugs Market Size by Country
10.3.1 South America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
10.3.2 South America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Anti-VEGF Intravitreal Drugs Market Size by Country
11.3.1 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Anti-VEGF Intravitreal Drugs Market Drivers
12.2 Anti-VEGF Intravitreal Drugs Market Restraints
12.3 Anti-VEGF Intravitreal Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Anti-VEGF Intravitreal Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Intravitreal Drugs
13.3 Anti-VEGF Intravitreal Drugs Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-VEGF Intravitreal Drugs Typical Distributors
14.3 Anti-VEGF Intravitreal Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Anti-VEGF Intravitreal Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Anti-VEGF Intravitreal Drugs Product and Services
Table 6. Roche Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Roche Recent Developments/Updates
Table 8. Novartis Basic Information, Manufacturing Base and Competitors
Table 9. Novartis Major Business
Table 10. Novartis Anti-VEGF Intravitreal Drugs Product and Services
Table 11. Novartis Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Novartis Recent Developments/Updates
Table 13. Biogen Basic Information, Manufacturing Base and Competitors
Table 14. Biogen Major Business
Table 15. Biogen Anti-VEGF Intravitreal Drugs Product and Services
Table 16. Biogen Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. Biogen Recent Developments/Updates
Table 18. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 19. Coherus BioSciences Major Business
Table 20. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product and Services
Table 21. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Coherus BioSciences Recent Developments/Updates
Table 23. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Regeneron Pharmaceuticals Major Business
Table 25. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product and Services
Table 26. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. Regeneron Pharmaceuticals Recent Developments/Updates
Table 28. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 29. Samsung Bioepis Major Business
Table 30. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product and Services
Table 31. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. Samsung Bioepis Recent Developments/Updates
Table 33. Biocon Biologics Basic Information, Manufacturing Base and Competitors
Table 34. Biocon Biologics Major Business
Table 35. Biocon Biologics Anti-VEGF Intravitreal Drugs Product and Services
Table 36. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 37. Biocon Biologics Recent Developments/Updates
Table 38. Qilu Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Qilu Pharma Major Business
Table 40. Qilu Pharma Anti-VEGF Intravitreal Drugs Product and Services
Table 41. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 42. Qilu Pharma Recent Developments/Updates
Table 43. Chengdu Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 44. Chengdu Kanghong Pharmaceutical Major Business
Table 45. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product and Services
Table 46. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 47. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 48. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 49. Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 50. Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 51. Market Position of Manufacturers in Anti-VEGF Intravitreal Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 52. Head Office and Anti-VEGF Intravitreal Drugs Production Site of Key Manufacturer
Table 53. Anti-VEGF Intravitreal Drugs Market: Company Product Type Footprint
Table 54. Anti-VEGF Intravitreal Drugs Market: Company Product Application Footprint
Table 55. Anti-VEGF Intravitreal Drugs New Market Entrants and Barriers to Market Entry
Table 56. Anti-VEGF Intravitreal Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 58. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 59. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 60. Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 61. Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 62. Global Anti-VEGF Intravitreal Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 63. Global Anti-VEGF Intravitreal Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 64. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 65. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 66. Global Anti-VEGF Intravitreal Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 67. Global Anti-VEGF Intravitreal Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 68. Global Anti-VEGF Intravitreal Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 69. Global Anti-VEGF Intravitreal Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 70. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 71. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 72. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 73. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 74. Global Anti-VEGF Intravitreal Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 75. Global Anti-VEGF Intravitreal Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 76. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 77. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 78. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 79. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 80. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 81. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 82. North America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 83. North America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 84. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 85. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 86. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 87. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 88. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 89. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 90. Europe Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 91. Europe Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 92. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 93. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 94. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 95. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 96. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 97. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 98. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 99. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 100. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 101. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 102. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 103. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 104. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 105. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 106. South America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 107. South America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 108. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 109. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 110. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 111. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 112. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 113. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 114. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 115. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 116. Anti-VEGF Intravitreal Drugs Raw Material
Table 117. Key Manufacturers of Anti-VEGF Intravitreal Drugs Raw Materials
Table 118. Anti-VEGF Intravitreal Drugs Typical Distributors
Table 119. Anti-VEGF Intravitreal Drugs Typical Customers
Table 1. Global Anti-VEGF Intravitreal Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Anti-VEGF Intravitreal Drugs Product and Services
Table 6. Roche Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Roche Recent Developments/Updates
Table 8. Novartis Basic Information, Manufacturing Base and Competitors
Table 9. Novartis Major Business
Table 10. Novartis Anti-VEGF Intravitreal Drugs Product and Services
Table 11. Novartis Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Novartis Recent Developments/Updates
Table 13. Biogen Basic Information, Manufacturing Base and Competitors
Table 14. Biogen Major Business
Table 15. Biogen Anti-VEGF Intravitreal Drugs Product and Services
Table 16. Biogen Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. Biogen Recent Developments/Updates
Table 18. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 19. Coherus BioSciences Major Business
Table 20. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product and Services
Table 21. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Coherus BioSciences Recent Developments/Updates
Table 23. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Regeneron Pharmaceuticals Major Business
Table 25. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product and Services
Table 26. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. Regeneron Pharmaceuticals Recent Developments/Updates
Table 28. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 29. Samsung Bioepis Major Business
Table 30. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product and Services
Table 31. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. Samsung Bioepis Recent Developments/Updates
Table 33. Biocon Biologics Basic Information, Manufacturing Base and Competitors
Table 34. Biocon Biologics Major Business
Table 35. Biocon Biologics Anti-VEGF Intravitreal Drugs Product and Services
Table 36. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 37. Biocon Biologics Recent Developments/Updates
Table 38. Qilu Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Qilu Pharma Major Business
Table 40. Qilu Pharma Anti-VEGF Intravitreal Drugs Product and Services
Table 41. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 42. Qilu Pharma Recent Developments/Updates
Table 43. Chengdu Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 44. Chengdu Kanghong Pharmaceutical Major Business
Table 45. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product and Services
Table 46. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 47. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 48. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 49. Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 50. Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 51. Market Position of Manufacturers in Anti-VEGF Intravitreal Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 52. Head Office and Anti-VEGF Intravitreal Drugs Production Site of Key Manufacturer
Table 53. Anti-VEGF Intravitreal Drugs Market: Company Product Type Footprint
Table 54. Anti-VEGF Intravitreal Drugs Market: Company Product Application Footprint
Table 55. Anti-VEGF Intravitreal Drugs New Market Entrants and Barriers to Market Entry
Table 56. Anti-VEGF Intravitreal Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 58. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 59. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 60. Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 61. Global Anti-VEGF Intravitreal Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 62. Global Anti-VEGF Intravitreal Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 63. Global Anti-VEGF Intravitreal Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 64. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 65. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 66. Global Anti-VEGF Intravitreal Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 67. Global Anti-VEGF Intravitreal Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 68. Global Anti-VEGF Intravitreal Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 69. Global Anti-VEGF Intravitreal Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 70. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 71. Global Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 72. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 73. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 74. Global Anti-VEGF Intravitreal Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 75. Global Anti-VEGF Intravitreal Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 76. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 77. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 78. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 79. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 80. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 81. North America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 82. North America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 83. North America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 84. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 85. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 86. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 87. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 88. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 89. Europe Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 90. Europe Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 91. Europe Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 92. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 93. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 94. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 95. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 96. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2021-2026) & (K Dose)
Table 97. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity by Region (2027-2032) & (K Dose)
Table 98. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 99. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 100. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 101. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 102. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 103. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 104. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 105. South America Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 106. South America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 107. South America Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 108. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2021-2026) & (K Dose)
Table 109. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Type (2027-2032) & (K Dose)
Table 110. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2021-2026) & (K Dose)
Table 111. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Application (2027-2032) & (K Dose)
Table 112. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2021-2026) & (K Dose)
Table 113. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity by Country (2027-2032) & (K Dose)
Table 114. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 115. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 116. Anti-VEGF Intravitreal Drugs Raw Material
Table 117. Key Manufacturers of Anti-VEGF Intravitreal Drugs Raw Materials
Table 118. Anti-VEGF Intravitreal Drugs Typical Distributors
Table 119. Anti-VEGF Intravitreal Drugs Typical Customers
LIST OF FIGURES
Figure 1. Anti-VEGF Intravitreal Drugs Picture
Figure 2. Global Anti-VEGF Intravitreal Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type in 2025
Figure 4. Ranibizumab Examples
Figure 5. Aflibercept Examples
Figure 6. Conbercept Examples
Figure 7. Brolucizumab Examples
Figure 8. Faricimab Examples
Figure 9. Other Examples
Figure 10. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application in 2025
Figure 12. Age-related Macular Degeneration Examples
Figure 13. Diabetic Macular Edema Examples
Figure 14. Retinal Vein Occlusion Examples
Figure 15. Other Examples
Figure 16. Global Anti-VEGF Intravitreal Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 17. Global Anti-VEGF Intravitreal Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 18. Global Anti-VEGF Intravitreal Drugs Sales Quantity (2021-2032) & (K Dose)
Figure 19. Global Anti-VEGF Intravitreal Drugs Price (2021-2032) & (US$/Dose)
Figure 20. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 21. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturer in 2025
Figure 22. Producer Shipments of Anti-VEGF Intravitreal Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 23. Top 3 Anti-VEGF Intravitreal Drugs Manufacturer (Revenue) Market Share in 2025
Figure 24. Top 6 Anti-VEGF Intravitreal Drugs Manufacturer (Revenue) Market Share in 2025
Figure 25. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 26. Global Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Region (2021-2032)
Figure 27. North America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 28. Europe Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 29. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 30. South America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 31. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 32. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 33. Global Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Type (2021-2032)
Figure 34. Global Anti-VEGF Intravitreal Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 35. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 36. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2032)
Figure 37. Global Anti-VEGF Intravitreal Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 38. North America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 39. North America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 40. North America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 41. North America Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 42. United States Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Canada Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. Mexico Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 45. Europe Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 46. Europe Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 47. Europe Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 48. Europe Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 49. Germany Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 50. France Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. United Kingdom Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Russia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. Italy Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 54. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 55. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 56. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 57. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Region (2021-2032)
Figure 58. China Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 59. Japan Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. South Korea Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. India Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Southeast Asia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. Australia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. South America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 65. South America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 66. South America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 67. South America Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 68. Brazil Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. Argentina Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 71. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 72. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 73. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 74. Turkey Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. Egypt Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. Saudi Arabia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. South Africa Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 78. Anti-VEGF Intravitreal Drugs Market Drivers
Figure 79. Anti-VEGF Intravitreal Drugs Market Restraints
Figure 80. Anti-VEGF Intravitreal Drugs Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs in 2025
Figure 83. Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs
Figure 84. Anti-VEGF Intravitreal Drugs Industrial Chain
Figure 85. Sales Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source
Figure 1. Anti-VEGF Intravitreal Drugs Picture
Figure 2. Global Anti-VEGF Intravitreal Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type in 2025
Figure 4. Ranibizumab Examples
Figure 5. Aflibercept Examples
Figure 6. Conbercept Examples
Figure 7. Brolucizumab Examples
Figure 8. Faricimab Examples
Figure 9. Other Examples
Figure 10. Global Anti-VEGF Intravitreal Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application in 2025
Figure 12. Age-related Macular Degeneration Examples
Figure 13. Diabetic Macular Edema Examples
Figure 14. Retinal Vein Occlusion Examples
Figure 15. Other Examples
Figure 16. Global Anti-VEGF Intravitreal Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 17. Global Anti-VEGF Intravitreal Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 18. Global Anti-VEGF Intravitreal Drugs Sales Quantity (2021-2032) & (K Dose)
Figure 19. Global Anti-VEGF Intravitreal Drugs Price (2021-2032) & (US$/Dose)
Figure 20. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 21. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturer in 2025
Figure 22. Producer Shipments of Anti-VEGF Intravitreal Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 23. Top 3 Anti-VEGF Intravitreal Drugs Manufacturer (Revenue) Market Share in 2025
Figure 24. Top 6 Anti-VEGF Intravitreal Drugs Manufacturer (Revenue) Market Share in 2025
Figure 25. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 26. Global Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Region (2021-2032)
Figure 27. North America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 28. Europe Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 29. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 30. South America Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 31. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 32. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 33. Global Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Type (2021-2032)
Figure 34. Global Anti-VEGF Intravitreal Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 35. Global Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 36. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2032)
Figure 37. Global Anti-VEGF Intravitreal Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 38. North America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 39. North America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 40. North America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 41. North America Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 42. United States Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Canada Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. Mexico Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 45. Europe Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 46. Europe Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 47. Europe Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 48. Europe Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 49. Germany Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 50. France Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. United Kingdom Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Russia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. Italy Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 54. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 55. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 56. Asia-Pacific Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 57. Asia-Pacific Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Region (2021-2032)
Figure 58. China Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 59. Japan Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. South Korea Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. India Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Southeast Asia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. Australia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. South America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 65. South America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 66. South America Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 67. South America Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 68. Brazil Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. Argentina Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 71. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 72. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 73. Middle East & Africa Anti-VEGF Intravitreal Drugs Consumption Value Market Share by Country (2021-2032)
Figure 74. Turkey Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. Egypt Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. Saudi Arabia Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. South Africa Anti-VEGF Intravitreal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 78. Anti-VEGF Intravitreal Drugs Market Drivers
Figure 79. Anti-VEGF Intravitreal Drugs Market Restraints
Figure 80. Anti-VEGF Intravitreal Drugs Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs in 2025
Figure 83. Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs
Figure 84. Anti-VEGF Intravitreal Drugs Industrial Chain
Figure 85. Sales Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source
